Schonfeld Strategic Advisors LLC Increases Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Schonfeld Strategic Advisors LLC grew its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 2.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,200 shares of the company’s stock after purchasing an additional 487 shares during the period. Schonfeld Strategic Advisors LLC’s holdings in Mirum Pharmaceuticals were worth $711,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Hennion & Walsh Asset Management Inc. grew its holdings in Mirum Pharmaceuticals by 25.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company’s stock valued at $6,021,000 after buying an additional 29,545 shares in the last quarter. AlphaQuest LLC boosted its position in shares of Mirum Pharmaceuticals by 969.6% during the 4th quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock valued at $76,000 after acquiring an additional 1,658 shares during the last quarter. Golden State Equity Partners grew its holdings in shares of Mirum Pharmaceuticals by 1,390.8% in the fourth quarter. Golden State Equity Partners now owns 19,380 shares of the company’s stock valued at $801,000 after purchasing an additional 18,080 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in Mirum Pharmaceuticals in the fourth quarter worth $277,000. Finally, Allspring Global Investments Holdings LLC purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at $413,000.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 57,606 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the transaction, the senior vice president now owns 4,841 shares of the company’s stock, valued at approximately $214,698.35. This trade represents a 92.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Peter Radovich sold 7,879 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $348,330.59. Following the completion of the sale, the chief operating officer now directly owns 18,672 shares of the company’s stock, valued at $825,489.12. The trade was a 29.67 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 92,764 shares of company stock valued at $4,109,161. 14.36% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on MIRM shares. JMP Securities lifted their price objective on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a “market outperform” rating in a research note on Friday. HC Wainwright boosted their price objective on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Finally, Robert W. Baird raised their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Buy” and an average price target of $59.00.

Mirum Pharmaceuticals Stock Down 2.1 %

Shares of MIRM opened at $44.27 on Friday. The firm has a market capitalization of $2.19 billion, a P/E ratio of -21.92 and a beta of 0.95. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.83 and a 12-month high of $54.23. The firm has a fifty day moving average price of $42.82 and a 200-day moving average price of $44.22. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. The business had revenue of $111.59 million for the quarter, compared to analyst estimates of $98.47 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company’s quarterly revenue was up 61.2% compared to the same quarter last year. During the same period last year, the company posted ($0.54) earnings per share. Equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.